These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20416859)

  • 1. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
    Hansel B; Bruckert E
    Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
    Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
    Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
    Steiner G; Urowitz MB
    Semin Arthritis Rheum; 2009 Apr; 38(5):372-81. PubMed ID: 18395771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
    Amezaga Urruela M; Suarez-Almazor ME
    Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk in patients with rheumatoid arthritis.
    Lauper K; Gabay C
    Semin Immunopathol; 2017 Jun; 39(4):447-459. PubMed ID: 28455580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.
    Kerola AM; Nieminen TV; Virta LJ; Kautiainen H; Kerola T; Pohjolainen T; Kauppi MJ; Puolakka K
    Clin Exp Rheumatol; 2015; 33(3):391-8. PubMed ID: 25936374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
    Toussirot É
    Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
    Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
    J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
    Danninger K; Hoppe UC; Pieringer H
    Int J Rheum Dis; 2014 Jul; 17(6):606-11. PubMed ID: 24931356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
    Rollefstad S; Ikdahl E; Hisdal J; Kvien TK; Pedersen TR; Holme I; Semb AG
    Ann Rheum Dis; 2015 Aug; 74(8):1544-50. PubMed ID: 24699940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis.
    Pašková U
    Ceska Slov Farm; 2019; 68(6):219-228. PubMed ID: 31906689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.